Oncovista Innovative Therapies I (OVIT) 0.0320 $OVIT
Oncovista Dormant
BusinessWire - Tue May 31, 11:36AM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company"
is dormant. On April 29, 2016, both William Brock and Alexander Ruckdaschal submitted their resignation from the Board of Directors of Oncovista. Consequently, the license rights of L-nucleoside conjugate OVI-117 will return to the licensor, Lipitek International, Inc.
Oncovista Receives Bridge Financing
BusinessWire - Tue Nov 03, 8:00AM CST
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista or the "Company" is pleased to announce it has received bridge financing from two funding sources recently. One funding source is Chicago Venture Partners of Chicago, IL, and the other is a high net worth individual. The funding will speed up the process of getting the company operational again. This was step one in the financing process, with a larger equity financing being the second step the company needs for continuation of clinical trials. The Company is working on a much larger equity deal for the funding of both trials.
Oncovista Retains Great Plains Capital as a Financial Advisor
BusinessWire - Tue Jun 30, 8:00AM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company" is pleased to announce it has retained Great Plains Capital Partners, LLC ("GPCP" or "advisor" as a financial advisor. GPCP, in a consultant capacity, will focus on strategic and corporate planning including assistance with mergers & acquisitions, and other strategic initiatives to ultimately help drive shareholder value for the investors of Oncovista. The Company recently settled a long-term litigation case that worked out to be very favorable, and plans to continue to advance and grow its pipeline.
Oncovista Settles 3 Year Litigation in New York Supreme Court
BusinessWire - Thu Jun 18, 4:57PM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company" is pleased to announce its 3 year litigation has been settled favorably in the New York Supreme Court. The company is in the process of obtaining a short-term bridge loan that will propel its operations forward. Oncovista has two cancer fighting drugs, one in Phase I and one in Phase I/II, and it expects to continue the clinical trials in advancement accordingly. The company has multiple strategic plans in place that will drive shareholder value over the coming years and the settlement being reached now allows for those plans to materialize. CEO Alexander Weis commented on the outcome of the settlement, "I am glad that we have settled the case and we will move forward quickly with our best, most efficient targeted anticancer drugs." Mr. Weis will work with his advisors and clinical development team to continue to grow the company and he is pleased with the result of this long-term litigation.
Oncovista Dormant
BusinessWire - Tue May 31, 11:36AM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company"
is dormant. On April 29, 2016, both William Brock and Alexander Ruckdaschal submitted their resignation from the Board of Directors of Oncovista. Consequently, the license rights of L-nucleoside conjugate OVI-117 will return to the licensor, Lipitek International, Inc. Oncovista Receives Bridge Financing
BusinessWire - Tue Nov 03, 8:00AM CST
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista or the "Company"
is pleased to announce it has received bridge financing from two funding sources recently. One funding source is Chicago Venture Partners of Chicago, IL, and the other is a high net worth individual. The funding will speed up the process of getting the company operational again. This was step one in the financing process, with a larger equity financing being the second step the company needs for continuation of clinical trials. The Company is working on a much larger equity deal for the funding of both trials. Oncovista Retains Great Plains Capital as a Financial Advisor
BusinessWire - Tue Jun 30, 8:00AM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company"
is pleased to announce it has retained Great Plains Capital Partners, LLC ("GPCP" or "advisor" as a financial advisor. GPCP, in a consultant capacity, will focus on strategic and corporate planning including assistance with mergers & acquisitions, and other strategic initiatives to ultimately help drive shareholder value for the investors of Oncovista. The Company recently settled a long-term litigation case that worked out to be very favorable, and plans to continue to advance and grow its pipeline. Oncovista Settles 3 Year Litigation in New York Supreme Court
BusinessWire - Thu Jun 18, 4:57PM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company"
is pleased to announce its 3 year litigation has been settled favorably in the New York Supreme Court. The company is in the process of obtaining a short-term bridge loan that will propel its operations forward. Oncovista has two cancer fighting drugs, one in Phase I and one in Phase I/II, and it expects to continue the clinical trials in advancement accordingly. The company has multiple strategic plans in place that will drive shareholder value over the coming years and the settlement being reached now allows for those plans to materialize. CEO Alexander Weis commented on the outcome of the settlement, "I am glad that we have settled the case and we will move forward quickly with our best, most efficient targeted anticancer drugs." Mr. Weis will work with his advisors and clinical development team to continue to grow the company and he is pleased with the result of this long-term litigation. 
